ARTICLE | Finance
Spinning out Sitryx
Why GSK decided to spin out immunometabolism company Sitryx with $30M series A
October 12, 2018 8:27 PM UTC
With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).
The round, which closed on Oct. 8, was co-led by seed investor SV Health Investors and new investor Sofinnova Partners, with participation from Longwood Fund and GSK...